

Table of Contents

- Preface p. ix
- Acknowledgements p. xi
- Corresponding Authors p. xiii
- Section 1 Introduction to Advanced Drug Delivery and Targeting
- Chapter 1 Drug Delivery: The Basic Concepts Anya M. Hillery p. 1
- 1.1 Introduction p. 2
- 1.2 The concept of bioavailability p. 3
- 1.3 The process of drug absorption p. 6
- 1.4 Pharmacokinetic processes p. 30
- 1.5 Timing for optimal therapy p. 33
- 1.6 Drug delivery considerations for the 'new biotherapeutics' p. 37
- 1.7 Conclusions p. 46
- 1.8 Further reading p. 47
- 1.9 Self-assessment questions p. 48
- Chapter 2 Drug Delivery: Market Perspectives Paul Evers p. 49
- 2.1 Introduction p. 50
- 2.2 Commercial importance of advanced drug delivery technologies p. 50
- 2.3 Market analysis p. 54
- 2.4 Industry evolution and structure p. 60
- 2.5 Further reading p. 61
- 2.6 Self-assessment questions p. 62
- Chapter 3 Advanced Drug Delivery and Targeting: An Introduction Anya M. Hillery p. 63
- 3.1 Terminology of drug delivery and targeting p. 64
- 3.2 Rate-controlled release in drug delivery and targeting p. 65
- 3.3 Drug targeting systems p. 69
- 3.4 Dosage forms for advanced drug delivery and targeting systems p. 70
- 3.5 Routes of administration p. 72
- 3.6 Strategies to increase drug absorption p. 78
- 3.7 Conclusions p. 81
- 3.8 Further reading p. 81
- 3.9 Self-assessment questions p. 81
- Chapter 4 Rate Control in Drug Delivery and Targeting: Fundamentals and Applications to Implantable Systems Hongkee Sah and Yie W. Chien p. 83
- 4.1 Introduction p. 84
- 4.2 Advantages and disadvantages of implantation therapy p. 85
- 4.3 Biocompatibility issues p. 87
- 4.4 Non-degradable polymeric implants p. 88
- 4.5 Biodegradable polymeric implants p. 99
- 4.6 Implantable pumps p. 107
- 4.7 Conclusions p. 113
- 4.8 Further reading p. 114
- 4.9 Self-assessment questions p. 114

- Chapter 5 Drug Targeting Systems: Fundamentals and Applications to Parenteral Drug Delivery Daan J.A. Crommelin and Wim E. Hennink and Gert Storm p. 117
- 5.1 Introduction p. 118
- 5.2 Soluble carriers for targeted drug delivery p. 127
- 5.3 Particulate carriers for drug targeting p. 131
- 5.4 Pharmaceutical aspects of carrier systems p. 139
- 5.5 Conclusions and prospects p. 142
- 5.6 Further reading p. 142
- 5.7 Self-assessment questions p. 143
- Section 2 Routes of Drug Delivery
- Chapter 6 Oral Drug Delivery Vincent H.L. Lee and Johnny J. Yang p. 145
- 6.1 Introduction p. 146
- 6.2 Structure and physiology of the GI tract p. 146
- 6.3 Physiological factors affecting oral bioavailability p. 150
- 6.4 Formulation factors affecting oral bioavailability p. 158
- 6.5 Advantages and disadvantages of oral drug delivery p. 163
- 6.6 Current technologies in oral drug delivery p. 166
- 6.7 New and emerging technologies in oral drug delivery p. 170
- 6.8 Conclusion p. 182
- 6.9 Further reading p. 182
- 6.10 Self-assessment questions p. 183
- Chapter 7 Oral Trans-Mucosal Drug Delivery Janet Hoogstraate and Luce Benes and Sophie Burgaud and Francoise Horriere and Isabelle Seyler p. 185
- 7.1 Introduction p. 186
- 7.2 Structure and physiology of the oral mucosa p. 186
- 7.3 Physiological factors affecting oral transmucosal bioavailability p. 189
- 7.4 Formulation factors affecting oral transmucosal bioavailability p. 192
- 7.5 Advantages and disadvantages of oral transmucosal drug delivery p. 193
- 7.6 Current technologies for oral transmucosal drug delivery p. 196
- 7.7 New and emerging technologies for oral transmucosal drug delivery p. 198
- 7.8 Conclusions p. 205
- 7.9 Further reading p. 205
- 7.10 Self-assessment questions p. 206
- Chapter 8 Transdermal Drug Delivery M. Begona Delgado-Charro and Richard H. Guy p. 207
- 8.1 Introduction p. 208
- 8.2 Structure and physiology of the skin p. 208
- 8.3 Factors affecting transdermal bioavailability p. 211
- 8.4 Advantages and disadvantages of transdermal drug delivery p. 216
- 8.5 Current technologies for transdermal drug delivery p. 217
- 8.6 New and emerging technologies for transdermal drug delivery p. 229
- 8.7 Conclusions p. 233
- 8.8 Further reading p. 234
- 8.9 Self-assessment questions p. 235
- Chapter 9 Nasal Drug Delivery Alison B. Lansley and Gary P. Martin p. 237
- 9.1 Introduction p. 238

- 9.2 Structure and physiology of the nasal cavity p. 238
- 9.3 Physiological factors affecting nasal bioavailability p. 248
- 9.4 Formulation factors affecting nasal bioavailability p. 253
- 9.5 Advantages and disadvantages of nasal drug delivery p. 256
- 9.6 Current technologies for nasal drug delivery p. 258
- 9.7 New technologies in nasal delivery p. 261
- 9.8 Conclusions p. 267
- 9.9 Further reading p. 267
- 9.10 Self-assessment questions p. 268
- Chapter 10 Pulmonary Drug Delivery Glyn Taylor and Ian Kellaway p. 269
- 10.1 Introduction p. 270
- 10.2 Structure and physiology of the lungs p. 270
- 10.3 Barriers to pulmonary drug delivery p. 275
- 10.4 Advantages and disadvantages of pulmonary drug delivery p. 286
- 10.5 Current technologies for pulmonary drug delivery p. 288
- 10.6 New technologies for pulmonary drug delivery p. 297
- 10.7 Conclusions p. 299
- 10.8 Further reading p. 300
- 10.9 Self-assessment questions p. 300
- Chapter 11 Vaginal Drug Delivery Hiroaki Okada and Anya M. Hillery p. 301
- 11.1 Introduction p. 302
- 11.2 Structure and physiology of the vagina p. 303
- 11.3 Physiological factors affecting vaginal drug delivery p. 304
- 11.4 Formulation factors affecting vaginal drug delivery p. 310
- 11.5 Advantages and disadvantages of vaginal delivery p. 312
- 11.6 Current technologies in vaginal drug delivery p. 315
- 11.7 New technologies in vaginal drug delivery p. 318
- 11.8 Conclusions p. 327
- 11.9 Further reading p. 327
- 11.10 Self-assessment questions p. 328
- Chapter 12 Ophthalmic Drug Delivery Clive G. Wilson and Y.P. Zhu and P. Kurmala and L.S. Rao and B. Dhillon p. 329
- 12.1 Introduction p. 330
- 12.2 Structure and physiology of the eye p. 332
- 12.3 Topical drug delivery p. 334
- 12.4 Intraocular drug delivery p. 346
- 12.5 Conclusions p. 352
- 12.6 Further reading p. 352
- 12.7 Self-assessment questions p. 353
- Chapter 13 Drug Delivery to the Central Nervous System William M. Pardridge and Pamela L. Golden p. 355
- 13.1 Introduction p. 356
- 13.2 Structure and function of the blood-brain barrier p. 356
- 13.3 Physiological factors affecting drug delivery to the CNS p. 358
- 13.4 Physicochemical factors affecting drug delivery to the CNS p. 360
- 13.5 Current technologies in CNS drug delivery p. 363

- 13.6 New technologies in CNS drug delivery p. 367
- 13.7 Conclusions p. 369
- 13.8 Further reading p. 369
- 13.9 Self-assessment questions p. 370
- Section 3 Future Directions of Drug Delivery and Targeting
- Chapter 14 Plasmid-based Gene Therapy Ram I. Mahato and Eric Tomlinson p. 371
- 14.1 Introduction p. 372
- 14.2 Gene expression systems p. 374
- 14.3 Gene delivery systems p. 377
- 14.4 Biodistribution and pharmacokinetics p. 383
- 14.5 Clinical applications of gene therapy p. 389
- 14.6 Conclusion p. 395
- 14.7 Further reading p. 396
- 14.8 Self-assessment questions p. 396
- Chapter 15 Integrating Drug Discovery and Delivery David Bailey and Andrew W. Lloyd p. 399
- 15.1 Introduction p. 400
- 15.2 Combinatorial chemistry p. 400
- 15.3 High-throughput screening p. 404
- 15.4 Genomics p. 405
- 15.5 Proteomics p. 413
- 15.6 Pharmacogenomics and pharmacoproteomics p. 415
- 15.7 Exploiting proteomics and genomics in drug targeting p. 416
- 15.8 Bioinformatics p. 417
- 15.9 Conclusions p. 418
- 15.10 Further reading p. 418
- 15.11 Self-assessment questions p. 419
- Chapter 16 New Generation Technologies Hongkee Sah and Yie W. Chien and Haesun Park and Sun-Joo Hwang and Kinam Park and Andrew W. Lloyd p. 421
- 16.1 Introduction p. 422
- 16.2 Rationalising drug design, discovery and delivery p. 422
- 16.3 The challenge of chronopharmacology p. 427
- 16.4 Epilogue p. 440
- 16.5 Further reading p. 441
- 16.6 Self-assessment questions p. 441
- Appendix p. 443
- Index p. 445